FDA Approves Unknown Drug — DYAX CORP.

DYAX Corporation has received FDA clearance for the investigational drug represented by BLA761090, a decision expected to serve as a catalyst for the company’s valuation as investors anticipate potential clinical metrics and commercial considerations. The approval validates the firm’s pipeline and will likely drive renewed investor interest and trading activity.